What is the challenge?

Despite intensive treatments involving months of chemotherapy, surgery and consolidation therapy with life threatening side effects and long-term disabilities, the survival today of children with high-risk NB is less than 40%. Cure First employs powerful, robotics-based high-throughput screening and the ability to inhibit gene function with small RNA molecules to identify targeted treatments in NB cells derived from individual children. We plan to continue testing for thousands of new possible combinations with retinoic acid, which is a relatively non-toxic drug already in use.

We have already published promising results for this approach (Toyoshima et al. PNAS, 2012; Cermelli et al, CSH Perspectives in Medicine, 2014; Grandori and Kemp, Future Oncology, 2013). Link to publications.

Our goal is to give children afflicted by NB and their families the chance for a happy life. We will translate the approach we take for NB to other cancers, and use the power of robotics, genomics and computers to identify personalized, targeted and less-toxic treatments for hundreds of childhood cancers.

Funds are still needed to pay for additional screens and the ongoing execution of our NB research. Please consider donating to support our Neuroblastoma Project either by giving to the Global Giving Neuroblastoma Project campaign or directly to Cure First where your donation will be deposited into the NB fund.

Read progress report here.


The Soupy for Loopy Foundation has made a big impact on OUR neuroblastoma research

JOHN MARIS, MD, of The Children's Hospital of Philadelphia Cancer Center, discusses the collaboration with Cure First to advance research on personalized and targeted treatments for pediatric NB. The generous support of the Soupy for Loopy Foundation has provided for the screening and analysis of ten live NB samples.


 

Proceeds from your donation will help fund Cure First's continuing efforts to discover new drug targets for children with neuroblastoma.